Shattuck Labs, Inc. (STTK) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Austin, TX, United States. The current CEO is Taylor H. Schreiber.
STTK has IPO date of 2020-10-09, 44 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $324.78M.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
